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ABSTRACT 
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 Olomoucine and Roscovitine are pharmacological inhibitors of cyclin-dependent kinases (CDK) 
displaying a promising profile as anticancer agents. Both compounds are effective inductors of apoptosis 
in a human neuroblastoma cell line, SH-SY5Y. The characterization of this process had suggested the 
involvement of an extrinsic pathway (Ribas and Boix, 2004), which depends on either Caspase 8 or 
Caspase 10 activation. However, neither Caspase 8 nor Caspase 10 is expressed in SH-SY5Y cells 
because of gene silencing. Upon Olomoucine or Roscovitine treatment, no re-expression of Caspase 8 or 
Caspase 10 was found. Therefore, in SH-SY5Y cells, this type of drugs is not triggering a canonical, 
Caspase 8/10-mediated, extrinsic apoptotic pathway. 
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1. Introduction 
Olomoucine and Roscovitine are drugs with an inhibitory effect on cyclin-dependent kinases 
(CDK). They are characterized by inhibiting CDK1, CDK2 and CDK5, but not CDK4 and CDK6. As a 
consequence, both compounds stop cell cycle and cell proliferation. In addition, apoptosis is also induced 
in many cell types. These cellular effects oppose neoplastic development and, as a consequence, 
neoplasia becomes an obvious target for these drugs (Knockaert et al., 2002).  
Little is known about the cellular events connecting drug-induced CDK dysfunction and apoptosis. 
In order to investigate these events, we have characterized the apoptotic process triggered by 
Olomoucine (200µM) and Roscovitine (50µM) in SH-SY5Y cells (Ribas and Boix, 2004). Our results have 
suggested the possibility of apoptosis being initiated at a membrane death receptor (Fas-like) and being 
transmitted by Caspase 8/10. However, Caspase8 and Caspase10 proteins are not expressed in SH-
SY5Y cells because of gene silencing due to DNA methylation (Eggert et al., 2001). Therefore, we 
hypothesized Olomoucine and Roscovitine could be inducing the re-expression of Caspase 8, Caspase 
10 or both, thus triggering apoptosis from an undetermined death receptor. By means of Western blot 
studies and, particularly, by a kinetic analysis of Caspase 8/10 activation, this hypothesis has been ruled 
out.  
 
2. Materials and Methods 
Roscovitine and Iso-Olomoucine were purchased from Calbiochem (San Diego, CA, USA). 
Olomoucine was acquired from Tocris (Bristol, UK). zVADfmk (Benzyloxycarbonyl-Val-Ala-Asp-
fluoromethylketone; Catalog # N-1510) was supplied by Bachem (Bubendorf, Switzerland). CellTiter 96® 
kit, containing the MTS reagent (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxy methoxyphenyl]-2-[4-
sulfophenyl]-2H-tetrazolium, inner salt), was provided by Promega (Madison, WI, USA). Cell viability (%) 
was measured by the capability of cells in culture to reduce MTS. Cell death (%) = 100 - cell  viability (%). 
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SH-SY5Y cells were grown in DMEM medium supplemented with 2 mM L-Glutamine. Jurkat cells 
were grown in RPMI medium. Final media contained 10% volume of fetal calf serum. The liquid media 
and the fetal calf serum were supplied by Invitrogen (Barcelona, Spain). Cell cultures were maintained in 
a 95% air, 5% CO2, water saturated atmosphere at 37°C. Drugs were dissolved in DMSO (Dimethyl 
Sulfoxide) to provide the stock solutions of Olomoucine (50 mM), Iso-Olomoucine (50 mM), Roscovitine 
(20 mM)  and zVADfmk (20 mM). From the stock solutions, drugs were added to the cultures at the final 
concentrations reported in the text and figures. Anti-Fas (human, activating), clone CH11, monoclonal 
antibody was supplied by Upstate biotechnology (Charlottesville, VA, USA) and used at the final 
concentrations further reported. 
Cells extracts for Western blot analysis were performed as follows. Cells were washed with PBS 
(Phosphate Buffered Saline) at 4°C and lysed with a lysis-buffer containing 1% Nonidet P-40 in 50 mM 
Tris/HCl (pH 7.2), 5 mM EDTA, 1 mM PMSF (Phenylmethanesulfonyl Fluoride), 2 µg/ml Aprotinin, 1 
µg/ml Leupeptin and 1 µg/ml Pepstatin. Pellets were gently disrupted by pipetting and extraction let to 
proceed on ice for 5 min. Following a centrifugation at 0 °C and 12000 g for 15 min, a clear supernatant 
devoid of nuclei was obtained. Protein concentration was determined by means of the DC Protein Assay 
(BioRad, Hercules, CA, USA) and equal protein loads were subjected to electrophoresis in 12% 
polyacrylamide gels. Then, proteins were transferred to PVDF (Polyvinylidene difluoride) membranes 
(Amersham, Buckinghamshire, UK) by means of a MINI trans-blot module from BioRad. Membranes 
were reacted with the following antibodies: Anti-Caspase 8 (1:250 dilution; Catalog # AM46T) from 
Oncogene Research Products (San Diego, CA, USA); Anti-Caspase 10 (1:1000 dilution; Catalog # M059-
3) from MBL (Woburn, MA, USA); Anti-αTubulin (1: 2000 dilution; Catalog # T5168) from Sigma (St. 
Louis, MO, USA). Secondary peroxidase conjugated antibodies were also from Sigma. Immunoblots were 
finally developed by means of the SuperSignal West Dura reagent from Pierce (Rockford, IL, USA).  
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 The kinetics and extent of effector Caspase activation (Caspase 3 and Caspase 7) was 
determined by the proteolysis of AcDEVDafc  (Acetyl-Asp-Glu-Val-Asp-7-amino-4-(trifluoromethyl) 
coumarin), a fluorogenic substrate measuring DEVDase activity. Assays on cultured cells in 96 multiwell 
plates were performed as we have reported before (Yuste et al., 2001; Ribas and Boix, 2004). The same 
procedure was applied to quantify the proteolysis of AcIETDafc (Acetyl-Ile-Glu-Thr-Asp-7-amino-4-
(trifluoromethyl) coumarin), a fluorogenic substrate for either Caspase 8 or Caspase 10 (IETDase activity). 
AcDEVDafc and AcIETDafc were obtained from Enzyme Systems Products (Livermore, CA, USA). 
 
3. Results 
In order to test if Olomoucine (200 µM) or Roscovitine (50 µM) were inducing apoptosis through 
the re-expression of Caspase 8 or Caspase 10 in SH-SY5Y cells, our first approach was to characterize 
the content of Caspase 8 and Caspase 10 zymogens in these cells facing these drugs. At 9 h of treatment 
most cells are either apoptotic or committed to apoptosis, this fact defined the time course shown in Fig. 
1. Even when films were overexposed, no band compatible with Caspase 8 zymogen was detected. 
Concerning Caspase 10 zymogen detection, the lack of specificity of some commercial antibodies had 
been reported (Kischkel et al., 2001). We tested some of those reported as specific and, indeed, they 
usually were in Jurkat extracts but not in SH-SY5Y ones (Fig. 1). However, despite of the background, no 
band with the mobility expected for Caspase 10 zymogen was found. We wondered if the activation by 
proteolyisis of the zymogens could mask the re-expression of Caspase 8/10. To control this event, we 
repeated the time course analysis in the presence of 100 µM zVADfmk, a general inhibitor of caspases. 
As seen in Fig. 1, the presence of zVADfmk made no difference. In conclusion, neither Caspase 8 nor 
Caspase 10 seemed to be re-expressed upon Olomoucine or Roscovitine treatments.  
To better support this result, we decided to perform an alternative approach, the kinetic analysis 
of caspase activation by these drugs (Fig. 2). Caspase 8 and Caspase 10 share very similar affinities 
towards the aminoacids they target. The motif IETD is cleaved by both enzymes. As a consequence, the 
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cleavage and afc (7-amino-4-(trifluoromethyl) coumarin) fluorochrom release from the synthetic peptide 
Ac-IETD-afc, provides a method to detect and quantify Caspase 8/10 activation (IETDase activity). 
Analogously, Caspase 3 and Caspase 7 show a similar affinity for the motif DEVD. Both are known to be 
effector caspases placed downstream of the apoptotic cascade of caspase activation. As a consequence, 
the fluorescence released by the cleavage of the synthetic peptide AcDEVDafc measures the activation of 
these effector capases (DEVDase activity). In addition, it indicates that apoptosis is taking place in the cell 
culture. 
 We proceeded to determine IETDase and DEVDase activities in SH-SY5Y cell cultures treated 
with either Olomoucine (200 µM) or Roscovitine (50 µM). As shown in Fig. 2, apoptosis and DEVDase 
activity increased in a time-dependent manner while IETDase activity was absent. As a negative control, 
we assayed Iso-Olomoucine (200 µM), an inactive isomer of Olomoucine, and as expected IETDase and 
DEVDase activities remained at basal levels (not shown). SH-SY5Y cells were also treated with a Fas 
activating antibody (CH11 clone). Different antibody concentrations were tested up to 250 ng/ml and 
neither IETDase nor DEVDase activities were seen (Fig. 2). 
In order to control the specificity of our approach and the activity of the CH11 antibody, Jurkat 
cells were studied. Jurkat cells are known to posses a functional Fas system that induces apoptosis upon 
stimulation by this antibody. As seen in Fig. 2, Caspase 8/10 dependent IETDase activity was already 
elevated at 6 h and decayed at 24 h, a time characterized by prominent cell destruction in the Jurkat 
culture. This result was consistent with the DEVDase activity profile from effector caspases, placed 
downstream of Caspase 8/10. In these cells, we thought of exploring the effects of Olomoucine (200 µM) 
and Roscovitine (50 µM). We found the profile of IETDase activity paralleled that of DEVDase one. Both 
activities increased in a time-dependent manner, thus emphasizing the near to zero value of the IETDase 
activity displayed by SH-SY5Y cells under the same treatment. In conclusion, Olomoucine and 
Roscovitine induce apoptosis in SH-SY5Y without the involvement of Caspase 8/10. 
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In each experiment, the extent of cell death induced by a 24 h treatment was controlled by means 
of the MTS reduction assay. The ratios of cell death obtained in SH-SY5Y were: 58.8 ± 8.8% for 
Olomoucine, 46.7 ± 8.4% for Roscovitine and -5.5 ± 1.5% for CH11 antibody. In Jurkat cells, the ratios 
were: 59.6 ± 19.7%, 61.3 ± 9% and 70.5 ± 4.5% respectively. The values are the mean ± S.E.M. from the 
experiments comprised in Fig. 2 and were consistent with those expected (Ribas and Boix, 2004). 
 
4. Discussion 
 In this report, we have used two independent methods to demonstrate the null implication of 
Caspase 8 and Caspase 10 in the apoptotic pathways triggered by Olomoucine and Roscovitine in SH-
SY5Y cells. In humans, Caspase 8 and Caspase 10 are constitutive elements of the apoptotic pathways 
initiated at cell membranes by death receptors, the so called extrinsic pathways (Ashkenazi and Dixit, 
1998). Therefore, the activation of a canonical, Caspase 8/10-mediated, extrinsic pathway is not the mode 
of action of two distinct CDK inhibitory drugs in this paradigmatic neuroblastoma cell line. 
  The procedure to determine caspase activation has been devised to be applied to multiwell plates 
(Yuste et al., 2001). As a consequence, pharmacological approaches envisaging multiple simultaneous 
determinations are easily performed. However, the specificity of fluorogenic peptide substrates has been 
questioned. To be conclusive, we believe a negative control like Iso-Olomoucine for Olomoucine is 
required. To assess specificity, we suggest the use of a positive control of the caspase activation 
subjected to study. Jurkat cells and CH11 antibody have provided the positive control of Caspase 8/10 
activation in our experiments. Moreover, Jurkat cells have also generated new information. First, 
Olomoucine and Roscovitine are effectively inducing apoptosis in this lymphoid cell line. Second, these 
drugs are activating Caspase 8/10 and, therefore, their involvement cannot be ruled out in these cells. 
However, Caspase 8 has been reported to be activated downstream of Caspase 3 (Slee, et al., 1999). 
Therefore, Caspase 8/10 could merely be amplifying and not triggering the caspase cascade in Jurkat 
cells. In conclusion, Caspase 8/10 implication in apoptosis triggered by Olomoucine and Roscovitine in 
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Jurkat cells can be a matter of discussion and future research however, as emphasized before, it can be 
definitively discarded in SH-SY5Y cells. 
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Fig. 1. Olomoucine and Roscovitine do not trigger Caspase 8/10 zymogen expression in SH-SY5Y cells. 
A) SH-SY5Y cells were treated with 200 µM Olomoucine for the times stated in the figure. Then, proteins 
were extracted and analyzed by Western Blot with primary antibodies against Caspase 8, Caspase 10 
and αTubulin (in order to control the amount of protein loaded per lane). B) SH-SY5Y cells were also 
treated with 50 µM Roscovitine and processed as described before. Note that some cells were 
simultaneously treated with zVADfmk (100 µM) in order to prevent zymogens to undergo autoproteolysis 
or proteolysis mediated by other caspases. Extracts from Jurkat cells were used as positive controls. 
 
 Fig. 2. Olomoucine and Roscovitine do not trigger Caspase 8/10 proteolytic activity in SH-SY5Y cells. 
Fluorogenic substrates of Caspase 8/10 (AcIETDafc, white bars) and effector Caspase 3/7 (AcDEVDafc, 
hatched bars) were used to determine the activation kinetics of these enzymes in SH-SY5Y and Jurkat 
cells treated with CH11 antibody (250 ng/ml), Olomoucine (200 µM) and Roscovitine (50 µM). Jurkat cells 
treated with the CH11 antibody were used as a positive control of Caspase 8/10 activation. The x axis is 
the time (h) elapsed after the treatment. The y axis is proteolytic activity measured in arbitrary fluorescent 
units. The bar value is the mean ± S.E.M. of two independent experiments with four independent 
determinations per experiment. 
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Fig. 2.  
 
 
